These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 25775909

  • 1. [Effectiveness of pharmacotherapy of irritated bowel syndrome from the standpoint of evidence based medicine].
    Sheptulin AA, Vize-Khripunova MA.
    Klin Med (Mosk); 2014; 92(7):64-8. PubMed ID: 25775909
    [Abstract] [Full Text] [Related]

  • 2. End points in irritable bowel syndrome.
    Mangel AW, Fehnel SE.
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Board Review Vignette: Irritable Bowel Syndrome.
    Talley NJ.
    Am J Gastroenterol; 2016 Sep; 111(9):1223-5. PubMed ID: 27527743
    [No Abstract] [Full Text] [Related]

  • 9. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
    Chang L, Lembo A, Sultan S.
    Gastroenterology; 2014 Nov; 147(5):1149-72.e2. PubMed ID: 25224525
    [No Abstract] [Full Text] [Related]

  • 10. Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.
    Prescrire Int; 2009 Apr; 18(100):75-9. PubMed ID: 19585728
    [Abstract] [Full Text] [Related]

  • 11. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI, Bouras EP.
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
    Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S, Amercian Gastroenterological Association.
    Gastroenterology; 2014 Nov; 147(5):1146-8. PubMed ID: 25224526
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Practical Evaluation and Management of Irritable Bowel Syndrome with Diarrhea: A Case Study Approach.
    Lacy BE.
    J Fam Pract; 2018 Aug; 67(8 suppl):S31-S36. PubMed ID: 30137051
    [No Abstract] [Full Text] [Related]

  • 17. Evidence-based medicine in practice: applying intention-to-treat analysis and perprotocol analysis.
    Schoenfeld PS.
    Am J Gastroenterol; 2005 Jan; 100(1):3-4. PubMed ID: 15654771
    [No Abstract] [Full Text] [Related]

  • 18. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul 14; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
    Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA.
    J Gastrointestin Liver Dis; 2009 Mar 14; 18(1):17-22. PubMed ID: 19337628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.